Semaglutide and Cardiovascular Outcomes In Patients With Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial
Mounjaro stands out because it works as a dual agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
Global burden of 87 risk factors in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019
Novo Nordisk owns the patent for semaglutide, meaning that compound versions of the drug are not allowed
GLP-1 Receptor Agonists: The Mechanism of Action Comedy Club Enter the heroes of our Hollywood tale: the GLP-1 receptor agonists
Researchers who lost their trusted supplier or who have been frustrated by payment friction, shipping delays, access restrictions, or fee surcharges at their current vendor are evaluating every option with more scrutiny than ever before